John Orwin, Atreca CEO
Bear market forces another biotech into layoffs, as antibody developer Atreca reduces headcount by more than 25%
Another biotech felt the chill of the bear market late Wednesday, engineering a round of layoffs in order to stay afloat through the end of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
